Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.63 |
| ▸ | CTSS | P25774 | 6/20 | 0.63 |
| ▸ | CTSL | P07711 | 5/20 | 0.63 |
| ▸ | KYNU | Q16719 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344382 | 1.00 | CTSK (0.63) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL29401640 | 1.00 | CTSK (0.63) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL3819501 | 0.95 | CTSK (0.64) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL31276793 | 0.95 | CTSK (0.64) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL3818440 | 0.91 | CTSS (0.63) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL1410812 | 0.91 | CTSK (0.61) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL607263 | 0.91 | CTSK (0.61) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL1409909 | 0.91 | CTSK (0.61) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL14479032 | 0.90 | CTSK (0.58) | CTSKCTSSCTSLKYNUALDH1A1 | |
| SCHEMBL1409906 | 0.90 | CTSK (0.60) | CTSKCTSSCTSLKYNUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109928971-B | Aryl substituted aminotetrahydropyrans and uses thereof | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-2669266-B1 | Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate | DONG A ST CO LTD (KR) | 2016-02-24 | — | — | EP | disclosed |
| WO-2015042397-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-2669266-A1 | Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate | Dong-A Pharmaceutical Co., Ltd. (KR) | 2013-12-04 | — | — | EP | disclosed |
| US-8598347-B2 | Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2013-12-03 | — | — | US | disclosed |
| EP-2415754-A2 | IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | CTSK 367/4885CTSS 584/4885CTSL 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.